First Patient Enrolled and Treated in the U.S. for EndoGastric Solutions, Inc.’s Randomized Study of Transoral Incisionless Fundoplication (TIF(R))

REDWOOD CITY, Calif.--(BUSINESS WIRE)--EndoGastric Solutions (EGS), the leader in the emerging field of Natural Orifice Surgery (NOS), today announced that the first patient has been enrolled and treated in the RESPECT study (Randomized EsophyX vs. Sham/Placebo Controlled Trial).